The FDA has approved 'Otarmeni', the first gene therapy for congenital hearing loss (DFNB9) caused by OTOF gene mutations.It ...
SereNeuro Therapeutics closed an oversubscribed pre-seed financing to advance its non-opioid pain therapy pipeline. The ...
For those in a hurry—a concise version summarizing only the main points is available on the blog.A rash that appeared after ...
Asianet Newsable on MSN
Stocktwits Pharma Pulse: JNJ earnings, cancer updates and two FDA target dates — The week’s biotech watchlist
JNJ reports third-quarter results on Tuesday, and Koyfin analysts expect modest revenue growth and lower earnings.
Effective management of high blood pressure could prevent more than 518,000 annual deaths from cardiovascular disease around ...
Engineers at the University of Bristol have developed a miniature liquid-metal pump weighing just 0.2 grams that could help ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results